Kong X-Q, Wang L-X, Kong D-G
Department of Cardiology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, PR China.
Lymphat Res Biol. 2007;5(1):45-7. doi: 10.1089/lrb.2007.5108.
Cardiac transplantation is one of the most effective treatments of end stage heart failure to date, although it comes with risks. One of the major complications of cardiac transplantation is allograft failure, which is caused by ischemic injuries, pulmonary hypertension and chronic rejection. Recent animal and human studies have demonstrated that cardiac lymphatic obstruction leads to significant myocardial fibrosis and depression in contractile forces. We hypothesize that lymphatic interruption, which is almost inevitable after cardiac transplantation, is a major cause of cardiac allograft failure through direct damages to the myocardium and also through the formation of allograft coronary vasculopathy.
心脏移植是迄今为止治疗终末期心力衰竭最有效的方法之一，尽管存在风险。心脏移植的主要并发症之一是同种异体移植失败，其由缺血性损伤、肺动脉高压和慢性排斥反应引起。最近的动物和人体研究表明，心脏淋巴管阻塞会导致显著的心肌纤维化和收缩力下降。我们推测，心脏移植后几乎不可避免的淋巴管中断是同种异体心脏移植失败的主要原因，其通过直接损伤心肌以及通过同种异体移植冠状动脉病变的形成导致失败。
